Evotec SE (EVO)
EVO moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How EVO actually reacts to news — the realized, point-in-time move the market made, measured across 110 labeled events over the last three years with zero look-ahead.
EVO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 40% | 93 |
| 30-min | 0.00% | 41% | 108 |
| 60-min | -0.18% | 40% | 109 |
| to close | 0.00% | 47% | 110 |
| Middle 50% of EVO reactions | -0.70% to +0.45% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 110 |
Half of all Evotec SE news events land between -0.70% and +0.45% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How EVO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 16 | 0.00% | 38% | +0.77% |
| Rating reiterations | 12 | -0.24% | 50% | -0.22% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how EVO ranks against every other measured name →
That’s how EVO usually reacts — get an email when it moves on news →Email me when EVO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to EVO's baseline. Nothing else.
Recent EVO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board | Press release | PR Newswire | -1.04% | -1.39% | |
| Form 6-K Evotec SE For: Oct 15 | SEC filing · Form 6-K | SEC EDGAR | -1.04% | -1.39% | |
| Form 6-K Evotec SE For: Oct 14 | SEC filing · Form 6-K | SEC EDGAR | -1.35% | -3.72% | |
| Evotec Announces Chief Scientific Officer Transition | Press release | PR Newswire | +0.00% | +2.50% | |
| Form 6-K Evotec SE For: Sep 29 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +2.50% | |
| Form 6-K Evotec SE For: Sep 09 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -1.09% | |
| Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies | Press release | PR Newswire | +0.00% | -1.09% | |
| Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors | Press release | PR Newswire | +0.00% | +1.06% | |
| Form 6-K Evotec SE For: Aug 13 | SEC filing · Form 6-K | SEC EDGAR | -0.49% | +0.00% | |
| Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases | Press release | PR Newswire | -0.19% | -2.01% | |
| Form 6-K Evotec SE For: Jul 13 | SEC filing · Form 6-K | SEC EDGAR | -0.23% | -1.38% | |
| Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook | Press release | PR Newswire | +4.49% | +3.85% | |
| Form 6-K Evotec SE For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | — | +0.18% | |
| Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics | Press release | PR Newswire | -0.49% | -1.75% | |
| Form 6-K Evotec SE For: Jun 17 | SEC filing · Form 6-K | SEC EDGAR | -0.95% | -0.76% | |
| Evotec Reports Results of the Annual General Meeting 2026 | Press release | PR Newswire | — | +2.26% | |
| Evotec Appoints Rui Wang as Head of Global In Silico and AI | Press release | ACCESS Newswire | +0.00% | -1.34% | |
| Evotec SE Successfully Placed €116.1 Million Convertible Bonds | Press release | ACCESS Newswire | +0.00% | +2.84% | |
| Form 6-K Evotec SE For: May 06 | SEC filing · Form 6-K | SEC EDGAR | -0.48% | +4.35% | |
| Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall | Press release | ACCESS Newswire | +0.31% | -1.89% | |
| Evotec Receives Grants to Advance Tuberculosis Treatment | Press release | ACCESS Newswire | +0.00% | +4.36% | |
| Form 6-K Evotec SE For: Apr 29 | SEC filing · Form 6-K | SEC EDGAR | — | +1.63% | |
| Evotec Announces New Nomination to Board of Directors | Press release | ACCESS Newswire | +0.00% | +4.36% | |
| Evotec SE to Announce First Quarter 2026 Results on May 6, 2026 | Press release | ACCESS Newswire | — | -1.34% | |
| Evotec Announces Chief Financial Officer Transition | Press release | ACCESS Newswire | +0.00% | +2.27% | |
| Form 6-K Evotec SE For: Apr 24 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +2.27% | |
| Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer | Press release | ACCESS Newswire | -0.31% | +0.94% | |
| Form 20-F Evotec SE For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | — | -0.37% | |
| Form 6-K Evotec SE For: Apr 08 | SEC filing · Form 6-K | SEC EDGAR | — | -0.37% | |
| Evotec Nominates Dieter Weinand as Supervisory Board Chairman | Press release | ACCESS Newswire | +0.39% | +0.39% | |
| Form 6-K Evotec SE For: Apr 07 | SEC filing · Form 6-K | SEC EDGAR | +0.39% | +0.00% | |
| Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer | Press release | ACCESS Newswire | — | +0.00% | |
| Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026 | Press release | ACCESS Newswire | — | +0.00% | |
| Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses | Press release | ACCESS Newswire | -0.68% | -2.06% | |
| Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation | Press release | ACCESS Newswire | -0.21% | +1.66% | |
| Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access | Press release | ACCESS Newswire | -0.41% | +0.27% | |
| Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations | Press release | ACCESS Newswire | +0.31% | +0.00% | |
| Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz | Press release | ACCESS Newswire | -0.31% | -5.35% | |
| Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome | Press release | ACCESS Newswire | +0.31% | +0.94% | |
| Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership | Press release | ACCESS Newswire | +0.33% | +1.95% | |
| Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities | Press release | ACCESS Newswire | +0.59% | -1.62% | |
| In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties | Press release | ACCESS Newswire | +0.59% | -1.62% | |
| Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025 | Press release | ACCESS Newswire | -0.24% | -0.24% | |
| Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb | Press release | ACCESS Newswire | +0.00% | -3.51% | |
| Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution | Press release | ACCESS Newswire | +0.27% | +1.60% | |
| Evotec SE to announce first half-year results 2025 on 13 August 2025 | Press release | ACCESS Newswire | -1.05% | -1.83% | |
| Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site | Press release | ACCESS Newswire | — | -2.80% | |
| Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site | Press release | ACCESS Newswire | — | -2.80% | |
| Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix | Press release | ACCESS Newswire | -1.23% | -0.54% | |
| Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance | Press release | ACCESS Newswire | -1.23% | -0.54% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the EVO section they belong to.
Where else EVO is measured.
EVO earnings → · Analyst actions → · SEC filings →
Other Financial Services names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Pimco Municipal Income Fund II Common Shares of Beneficial Interest (PML) | 112 | -0.06% | 36% |
| Eaton Vance New York Municipal Bond Fund Common Shares of Beneficial Interest, $.01 par value (ENX) | 110 | 0.00% | 50% |
| RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. (OPP) | 110 | 0.00% | 50% |
| Virginia National Bankshares Corporation (VABK) | 110 | +0.25% | 56% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Financial Services names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Evotec SE's median reaction calculated?
Every labeled EVO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 110 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of EVO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does EVO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.